Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary mediastinal B-cell lymphoma.

E Boleti1, P W M Johnson

  • 1Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton, UK. ekaterini.boleti@suht.nhs.uk

Hematological Oncology
|June 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

British journal of haematology·2026
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Engineering antibody molecules.

Methods in molecular medicine·2011
Same author

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519).

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Primary mediastinal B-cell lymphoma (PMBCL) management is debated. The IELSG 26 study aims to prospectively gather data on optimal chemotherapy, radiotherapy, and rituximab use for this NHL subtype.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pathology

Background:

  • Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of diffuse large B-cell lymphoma, comprising about 5% of non-Hodgkin's lymphomas.
  • PMBCL shares clinical and molecular features with nodular sclerosing Hodgkin lymphoma.
  • Optimal management strategies for PMBCL are currently debated.

Purpose of the Study:

  • To address uncertainties in the optimal management of PMBCL.
  • To investigate the efficacy of weekly alternating chemotherapy regimens versus CHOP.
  • To determine the necessity of consolidation radiotherapy and the role of PET scanning in treatment decisions.
  • To evaluate the impact of rituximab on PMBCL treatment outcomes.

Main Methods:

  • The study is a prospective clinicopathologic investigation.

Related Experiment Videos

  • The International Extranodal Lymphoma Study Group (IELSG) 26 study is designed to gather data on PMBCL.
  • Focus on evaluating different therapeutic approaches including chemotherapy, radiotherapy, and rituximab.

    • Main Results:

    • Data collection is ongoing as the study has recently opened.
    • Prospective data gathering aims to provide insights into treatment efficacy.
    • The study will analyze outcomes based on various management strategies.

    Conclusions:

    • The IELSG 26 study represents a significant effort to clarify PMBCL management.
    • Findings are expected to guide future treatment protocols for PMBCL.
    • This research aims to improve therapeutic outcomes for patients with this lymphoma subtype.